Twelfth Annual Mastering Medicinal Chemistry

Cambridge Healthtech Institute’s Twelfth Annual Mastering Medicinal Chemistry will showcase informative, high quality case studies and successful strategies to tackle the problems facing the medicinal chemistry landscape. The 2015 program will include case studies, panel discussions and intimate, collaborative roundtable discussions from senior executives and leading scientists around hot topics in medicinal chemistry and medicinal chemistry strategy.

Preliminary Agenda

 EVOLVING THE KINOME IN DRUG DISCOVERY

Kinase Drug Discovery Past, Present, and Future

Mark Bunnage, Ph.D., Vice President, Worldwide Medicinal Chemistry, Pfizer

Secreted Kinase/Extracellular Kinases

Malcolm Whitman, Ph.D., Professor, Department of Developmental Biology, Harvard School of Dental Medicine; Department of Cell Biology, Harvard Medical School

Akt and RNA Metabolism

Philip N. Tsichlis, M.D., Jane F Desforges Professor of Medicine, Tufts University School of Medicine

EMERGING GENE FAMILIES BEYOND GPCR AND KINASES 

The Medicinal Chemistry of Solute Carrier Proteins (SLCs)

David Hepworth, Ph.D., Head, Medicinal Chemistry, Inflammation and Remodeling, Pfizer, Inc.

Targeting IAP and BCL Protein-Protein Interactions with Small Molecules: Lessons Learned

Brian Aquila, Ph. D., Associate Director, Chemistry, AstraZeneca

HIT GENERATION & DISCOVERY TECHNOLOGIES: DNA ENCODED LIBRARIES, PHENOTYPIC SCREENS & BEYOND

Hit Generation Technologies – From DNA Encoded Libraries & Phenotypic Screens, to New Chemical Space

Jörg Holenz, Ph.D., Director, Discovery and Preclinical Sciences, Project Leader, AstraZeneca Pharmaceuticals LP

 Direct and Synergistic Inhibition of the HCV NS5A Replication Complex

Makonen Belema, Ph.D., Principal Scientist, Discovery Chemistry, Bristol-Myers Squibb Co.

Triage of High-Throughput Screening Hits: A PAIN in the Assay

Jonathan B. Baell, Ph.D., Professor, Larkins Fellow, Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Science, Monash Institute of Pharmaceutical Sciences

COVALENT AND IRREVERSIBLE INHIBITORS

Covalent Inhibitors as an Approach for Challenging Targets

Atli Thorarensen, Ph.D., Research Fellow, BioTx Medicinal Chemistry, Pfizer

WATER IN DRUG DISCOVERY: COMPUTATIONAL & NEXT GENERATION DESIGN 

Water in Drug Discovery: Computational Design

José Duca, Ph.D., Head, Computer-Aided Drug Discovery, Novartis

Designing Water-Soluble Molecules in Drug Discovery

Michael A. Walker, Ph.D., Principal Scientist, Medicinal Chemistry, Bristol-Myers Squibb Pharmaceutical Research and Development

FUTURE ROLE OF MEDICINAL CHEMISTRY – SCIENCE, TECHNOLOGY & STRATEGY 

Target Validation and Reproducibility - A Chemistry Perspective

Mark Bunnage, Ph.D., Vice President, Worldwide Medicinal Chemistry, Pfizer

Outsourcing of Medicinal Chemistry

David Bauer, Principal Scientist, Head of Medicinal Chemistry Outsourcing, Amgen

Pre-Competitive Collaboration

Pamela Hill, Open Innovation Program Manager, Emerging Innovations, AstraZeneca, R&D Boston

Start-Up Perspective

Eddine Saiah, Ph.D., Vice President, Drug Discovery, Navitor Pharmaceuticals

For questions or suggestions about the meeting, please contact:
Edel O’Regan, Ph.D.
Vice President, Conferences
Cambridge Healthtech Institute
T: (+1) 781-972-5423
E: eoregan@healthtech.com

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Joseph Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com